Infectious Disease: CARG-201

- Functional cure for chronic HBV patients
- Enables robust expression and secretion of HBV middle S and core antigens in vitro
- Induces broad immune responses
- Results in reduction HBV marker surface antigens by more than 2 logs in AAV model
- Eliminates virus as monotherapy or in combination with standard antiviral therapy
- Pre-IND meeting with the FDA held in 2019
- Upon successful financing IND filing will be submitted in Q1, 2024
- IND is planned to be filed with the FDA by the end of 2023